Modified Butterfly Graft Still Effective Tool in Rhinoplasty

This article originally appeared here.
Share this content:
Modified Butterfly Graft Still Effective Tool in Rhinoplasty
Modified Butterfly Graft Still Effective Tool in Rhinoplasty

MONDAY, July 11, 2016 (HealthDay News) -- For patients undergoing rhinoplasty with a modified butterfly graft, there is a decrease in the Nasal Obstruction Symptoms Evaluation score, according to a study published online July 7 in JAMA Facial Plastic Surgery.

Myriam Loyo, M.D., from Oregon Health and Science University in Portland, and colleagues conducted a retrospective review to analyze outcomes of adults who had undergone primary or secondary rhinoplasty with butterfly grafting. Thirty-four patients (23 women, 11 men) were included in the case series.

The researchers found that the mean graft length was 3.4 cm and the mean width 0.9 cm. After surgery there was a significant decrease in the Nasal Obstruction Symptoms Evaluation score (mean preoperative score, 69 versus mean postoperative score, 23). Seventy-four, 18, and 3 percent of patients rated their appearance as improved or unchanged, minimally worse, and much worse, respectively. Fifty-nine masked observers participated in the study; they observed the graft 59.7 percent of the time that it was present. Its presence was suspected in 36.5 percent of cases when it was not present.

"The modified butterfly graft is a longer and thinner graft than the originally described butterfly graft. It is still an effective tool in the treatment of nasal obstruction with acceptable visibility," the authors write. "In most cases, it is difficult for health care professionals to identify the presence of the graft."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »